Contact: Bill Schaller
Dana-Farber Cancer Institute
Caption: Mary-Ellen Taplin, M.D., of Dana-Farber Cancer Institute, and colleagues have demonstrated that a hormone-depleting drug approved for the treatment of metastatic prostate cancer can help eliminate or nearly eliminate tumors in many patients with aggressive cancers that have yet to spread beyond the prostate, according to a clinical study to be presented at the annual meeting of the American Society of Clinical Oncology June 1-5 in Chicago.
Credit: Sam Ogden
Usage Restrictions: None
Related news release: Hormone-depleting drug shows promise against localized high-risk prostate tumors